Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-08-06
2011-10-04
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S328000
Reexamination Certificate
active
08030280
ABSTRACT:
The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to enhance their immunogenicity and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use.
REFERENCES:
patent: 5262177 (1993-11-01), Brown et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5620886 (1997-04-01), Brichard et al.
patent: 5679511 (1997-10-01), Kwon
patent: 5837476 (1998-11-01), Brichard et al.
patent: 5844075 (1998-12-01), Kawakami et al.
patent: 5854203 (1998-12-01), Brichard et al.
patent: 5856091 (1999-01-01), Brichard et al.
patent: 5994523 (1999-11-01), Kawakami et al.
patent: 6001975 (1999-12-01), Brichard et al.
patent: 6201111 (2001-03-01), Brichard et al.
patent: 6270778 (2001-08-01), Kawakami et al.
patent: 6500919 (2002-12-01), Adema et al.
patent: 6537560 (2003-03-01), Kawakami et al.
patent: 6660276 (2003-12-01), Slingluff et al.
patent: 7232887 (2007-06-01), Kawakami et al.
patent: 2003/0216559 (2003-11-01), Adema et al.
patent: 2004/0156861 (2004-08-01), Figdor et al.
patent: 2007/0259422 (2007-11-01), Kawakami et al.
patent: 2008/0233637 (2008-09-01), Kawakami et al.
patent: 2009/0232839 (2009-09-01), Figdor et al.
patent: 3341367 (1984-05-01), None
patent: 0668350 (1995-08-01), None
patent: 2133543 (1984-08-01), None
patent: WO 92/21767 (1992-12-01), None
patent: 9314189 (1993-07-01), None
patent: WO 94/21126 (1994-09-01), None
patent: 9423067 (1994-10-01), None
patent: 9522561 (1995-08-01), None
patent: WO 96/01557 (1996-01-01), None
Coulie, P.G. et al. (1993) “Genes coding for tumor antigens recognized by human cytolytic T-lymphocytes”J. Immunotherap.14:104-109.
Coulie P.G. et al. “A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas”,J. Exp. Med(1994) 180:35-42.
Maresh, C.A. et al.: Cloning and expression of the gene for the melanoma associated ME20 antigen.DNA and Cell Biology, 1994; 13:87-95.
Cox, A.L., et al. “Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines”Science1994; 264:716-719.
Brichard, V., et al.: “The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas”.J. Exp. Med.1993; 178:489-495.
Gaugler, B., et al. “Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes”.J. Exp. Med.1994; 179:921-930.
Traversari, C., et al.: “A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E”.J Exp. Med.1992; 176:1453-1457.
Cellis, E., et al.: “Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptides cpitopes”.Proc. Natl. Acad. Sci.U.S.A. 1994; 91:2105-2109.
Boon, T.: “Toward a genetic analysis of tumor rejection antigens”.Adv. Cancer Res.1992; 58:177-210.
Kawakami, Y., et al.; T-cell recognition of human melanoma antigens.J. Immunother.1993; 14:88-93.
Bakker, A.B.H., et al.: Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor infiltrating lymphocytes.J. Exp. Med.1994; 179:1005-1009.
Wölfel, T., et al.: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T. lymphocytes.Eur. J. Immunol.1994; 24: 759-764.
Adema, G.J., et al.: Melanocyte lineage-specific antigens recognized by monoclonal antibodies NK1-beteb, HMB-50, and HMB-45 are encoded by a single cDNA.Am J. Pathol.1993; 143: 1579-1585.
Kwon, B.S., et al.: A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12.Proc. Natl. Acad. Sci.USA 1991; 88: 9228-9232.
Rosenberg, S.A., et al.: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report.N. Engl. J. Med.1988; 319: 1676-1680.
Kawakami, Y., et al.,: Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas.J Immunol1992; 148: 638-643.
Van der Bruggen, et al.: A gene encoding an antigen recognized by cytolytic T. lymphocytes on a human melanoma.Science1991; 254: 1643-1647.
Falk, K., et al.: “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.”Nature1991, 351: 290-296.
Kubo, R., et al.: “Definition of specific peptide motifs for four major HLA-A Alleles.”Journal of Immunology1994, 152: 3913-3924.
Parker, K., et al.: “Sequence motifs important for peptide binding to the human MHC class I molecule. HLA-A2.” 1992, J. Immunol: 3580-3587.
Ruppert, J., et al.: “Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules.”Cell1993, 74: 929-937.
Storkus, W., et al.: “Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.”Journal of Immunology1993, 151: 3719-3727.
Kawakami, Y., et al.: “Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.”Pro. Natl. Acad. Sci.USA 1994, 91: 3515-3519.
Adema, G.J. et al., “Molecular characterization of the melanocyte lineage-specific antigen gp100.”Journal of Biological Chemistry1994, 269: 20126-20133.
EMBL Database Accession No. M32295: 26-11-90 Vogel A.: Human KD melanocyte specific secreted glycoprotein MRNA 3'end'.
Kawakami, Y., et al., “Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection”PNAS91: 6458-6462 1994.
Kawakami, Y., et al., “Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes”J. Exp. Med.180: 347-352, 1994.
Rivoltini, L., et al., “Induction of Tumor-Reactive CTL from Peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1”Journal of Immunology, 1995, 154: 2257-2265.
Slingluff, C.L., Jr., et al., “Direct analysis of tumor-associated peptide antigens”Current Opinion in Immunology1994, 6: 733-740.
Cole, D.J., et al., “Characterization of the Functional Specificity of a Cloned T-Cell Receptor Heterodimer Recognizing the MART-1 Melanoma Antigen”Cancer Res.55: 748-752 Feb. 1995.
Cole, D.J., et al., “Identification of MART-1-specific T-Cell Receptors: T Cells Utilizing Distinct T-Cell Receptor Variable and Joining Regions Recognize the Same Tumor Epitope”Cancer Res.54: 5265-5268, 1994.
Castelli, C., et al., “Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by CD8+Cytotoxic T Lymphocytes”J. Exp. Med.181: 363-368 1995.
Sette, A., et al., “Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays”Molecular Immunology31: 813-822, 1994.
Wölfel, T., et al., “Analysis of Antigens Recognized on Human Melanoma Cells by A2-Restricted Cytolytic T Lymphocytes (CTL)”Int. J. Cancer55: 237-244, 1993.
Wölfel, T., et al., “Isolation of Naturally Processed Peptides Recognized by Cytolytic Lymphocytes (CTL) on Human Melanoma Cells in Association With HLA-A2.1”Int. J. Cancer57: 413-418, 1994.
Topalian, S.L., et al., “Human CD4+T Cells Specifically Recognize a Shared Melanoma-Associated Antigen Encoded by the Tyrosinase Gene”PNAS91: 9461-9465, 1994.
Boël, P., et al., “BAGS: a New Gene Encoding an Antigen Recognized
Kawakami Yutaka
Rosenberg Steven A.
Huff Sheela J
Leydig & Voit & Mayer
The United States of America as represented by the Secretary, De
LandOfFree
Melanoma antigens and their use in diagnostic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Melanoma antigens and their use in diagnostic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanoma antigens and their use in diagnostic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298501